Atazanavir-d<sub>6</sub>

Atazanavir-d6

CAT N°: 26456
Price:

365.00 310.25

Atazanavir-d6 is intended for use as an internal standard for the quantification of atazanavir (Item No. 11733) by GC- or LC-MS. Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM).{24185} It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50 values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.{24184} Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-di(methyl-d3) ester
  • Correlated keywords
    • HIV1 GCMS LCMS UGT-1A1 Reyataz BMS232632 CGP73547 BMS 232632 CGP 73547
  • Product Overview:
    Atazanavir-d6 is intended for use as an internal standard for the quantification of atazanavir (Item No. 11733) by GC- or LC-MS. Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM).{24185} It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50 values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.{24184} Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.

We also advise you